BELSOMRA TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SUVOREXANT

Saadav alates:

MERCK CANADA INC

ATC kood:

N05CJ01

INN (Rahvusvaheline Nimetus):

SUVOREXANT

Annus:

15MG

Ravimvorm:

TABLET

Koostis:

SUVOREXANT 15MG

Manustamisviis:

ORAL

Ühikuid pakis:

30

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0160930003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2020-05-14

Toote omadused

_BELSOMRA™ (suvorexant)_
_ _
_Page 1 of 37 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
BELSOMRA
®
Suvorexant
Tablet
10 mg, 15 mg, 20 mg
Oral
Hypnotic
Merck Canada Inc.
16750 route Transcanadienne
Kirkland, QC Canada H9H 4M7
www.merck.ca
Date of Initial Approval:
November 28, 2018
Date of Revision:
March 4, 2021
Submission Control No: 244781
_ _
_BELSOMRA_
_®_
_ (suvorexant)_
_ _
_Page 2 of 37_
RECENT MAJOR LABEL CHANGES
WARNINGS AND PRECAUTIONS
02/2021
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
1
INDICATIONS
...............................................................................................................
3
1.1
Pediatrics
.............................................................................................................
3
1.2
Geriatrics
.............................................................................................................
3
2
CONTRAINDICATIONS
................................................................................................
3
3
DOSAGE AND
ADMINISTRATION...............................................................................
3
3.1
Dosing Considerations
.........................................................................................
3
3.2
Recommended Dose and Dosage Adjustment
..................................................... 4
3.3
Missed Dose
........................................................................................................
5
4
OVERDOSAGE
.............................................................................................................
5
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
....................... 5
6
WARNINGS AND PRECAUTIONS
...............................................................................
6
6.1
Special Populations
.............................................................................................
9
6.1.1
Pregnant Women
.........................................................